10X GENOMICS (Germany) Performance
| 1KJ Stock | EUR 12.61 0.07 0.56% |
The firm shows a Beta (market volatility) of -0.7, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning 10X GENOMICS are expected to decrease at a much lower rate. During the bear market, 10X GENOMICS is likely to outperform the market. At this point, 10X GENOMICS DL has a negative expected return of -0.54%. Please make sure to confirm 10X GENOMICS's total risk alpha, maximum drawdown, skewness, as well as the relationship between the treynor ratio and potential upside , to decide if 10X GENOMICS DL performance from the past will be repeated sooner or later.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days 10X GENOMICS DL has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
10X |
10X GENOMICS Relative Risk vs. Return Landscape
If you would invest 1,984 in 10X GENOMICS DL on September 23, 2024 and sell it today you would lose (723.00) from holding 10X GENOMICS DL or give up 36.44% of portfolio value over 90 days. 10X GENOMICS DL is currently producing negative expected returns and takes up 5.3417% volatility of returns over 90 trading days. Put another way, 47% of traded stocks are less volatile than 10X, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
10X GENOMICS Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for 10X GENOMICS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as 10X GENOMICS DL, and traders can use it to determine the average amount a 10X GENOMICS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1014
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | 1KJ |
Estimated Market Risk
| 5.34 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.54 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average 10X GENOMICS is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of 10X GENOMICS by adding 10X GENOMICS to a well-diversified portfolio.
10X GENOMICS Fundamentals Growth
10X Stock prices reflect investors' perceptions of the future prospects and financial health of 10X GENOMICS, and 10X GENOMICS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on 10X Stock performance.
| Return On Equity | -0.21 | |||
| Return On Asset | -0.0892 | |||
| Profit Margin | (0.33) % | |||
| Operating Margin | (0.28) % | |||
| Shares Outstanding | 95.6 M | |||
| Revenue | 503.71 M | |||
| EBITDA | (117.15 M) | |||
| Cash And Equivalents | 621.96 M | |||
| Cash Per Share | 5.66 X | |||
| Total Debt | 70.82 M | |||
| Debt To Equity | 0.09 % | |||
| Book Value Per Share | 6.78 X | |||
| Cash Flow From Operations | (219.4 M) | |||
| Earnings Per Share | (0.76) X | |||
About 10X GENOMICS Performance
By analyzing 10X GENOMICS's fundamental ratios, stakeholders can gain valuable insights into 10X GENOMICS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if 10X GENOMICS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if 10X GENOMICS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California. 10X GENOMICS operates under Health Information Services classification in Germany and is traded on Frankfurt Stock Exchange. It employs 852 people.Things to note about 10X GENOMICS DL performance evaluation
Checking the ongoing alerts about 10X GENOMICS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for 10X GENOMICS DL help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| 10X GENOMICS DL generated a negative expected return over the last 90 days | |
| 10X GENOMICS DL has high historical volatility and very poor performance | |
| The company reported the revenue of 503.71 M. Net Loss for the year was (504.02 M) with profit before overhead, payroll, taxes, and interest of 416.4 M. | |
| 10X GENOMICS DL has accumulated about 621.96 M in cash with (219.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.66. | |
| Over 100.0% of the company shares are owned by institutions such as pension funds |
- Analyzing 10X GENOMICS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether 10X GENOMICS's stock is overvalued or undervalued compared to its peers.
- Examining 10X GENOMICS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating 10X GENOMICS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of 10X GENOMICS's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of 10X GENOMICS's stock. These opinions can provide insight into 10X GENOMICS's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for 10X Stock analysis
When running 10X GENOMICS's price analysis, check to measure 10X GENOMICS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 10X GENOMICS is operating at the current time. Most of 10X GENOMICS's value examination focuses on studying past and present price action to predict the probability of 10X GENOMICS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 10X GENOMICS's price. Additionally, you may evaluate how the addition of 10X GENOMICS to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |